# An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02324491` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02324491](<https://clinicaltrials.gov/study/NCT02324491>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02324491

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 152 participants.

## Technical summary

Registry record NCT02324491. Randomized; triple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 152 participants (enrolled count; ClinicalTrials.gov record NCT02324491, source copy `cardio:ctgov-nct02324491-2016-01-06`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02324491, source copy `cardio:ctgov-nct02324491-2016-01-06`, retrieved 2026-10-26)
- Primary completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02324491, source copy `cardio:ctgov-nct02324491-2016-01-06`, retrieved 2026-10-26)
- Completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02324491, source copy `cardio:ctgov-nct02324491-2016-01-06`, retrieved 2026-10-26)
- Countries: Australia (ClinicalTrials.gov record NCT02324491, source copy `cardio:ctgov-nct02324491-2016-01-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02324491-2016-01-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
- Condition: Obesity
- Condition: Type 2 Diabetes
- Intervention (Drug): ZGN-440 for Injectable Suspension
- Intervention (Drug): ZGN-440 Placebo for Injectable Suspension
- Lead sponsor: Zafgen, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial (`cardio:pubmed-29992370`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9fc203ede5872a5316c4266c371a738bcccd810f2c3974d13ae769ecbdb21b0c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
